Exchange: NYSE·Updated 07:30 PM EDT

GKOS News

News
all
press releases
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.read more...
Benzinga
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.read more...
Benzinga
More News
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
Glaukos Reports Positive Phase 4 Results For IDose TR With Cataract Surgery
(RTTNews) - Friday, Glaukos Corporation (GKOS) announced positive topline results from a Phase 4 study evaluating iDose TR in combination with cataract surgery in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT...
Nasdaq News: Markets
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose TR in Combination with Cataract Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical...
Business Wire
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.read more...
Benzinga
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and...
Business Wire
Glaukos Announces Positive Three-Year Epioxa Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating...
Business Wire
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.
Zacks
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28...
Business Wire
If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 2.33% on an annualized basis producing an average annual return of 16.15%. Currently, Glaukos has a market capitalization of $9.53 billion.read more...
Benzinga

Advertisement|Remove ads.